Want to see GLMD full AI Analyst Report?
Top Page
Galmed Pharmaceuticals
(NASDAQ:GLMD)
Select Model
Select Model
Rating:44Neutral
Price Target:
$4.50
▲(782.35% Upside)
Action:Reiterated
Date:08/20/26
GLMD scores low primarily due to weak financial performance (no revenue, persistent losses, and ongoing cash burn with declining equity). Technicals add modest pressure as the stock trades below major moving averages with slightly negative MACD. Valuation does not provide support because the company is unprofitable (negative P/E) and has no dividend yield data.
Positive Factors
Minimal Leverage
Near-zero debt limits interest obligations and reduces balance-sheet risk while Galmed funds development. This provides greater financial flexibility than a highly leveraged biotech, although the benefit is constrained by ongoing cash burn.
Negative Factors
No Revenue and Persistent Losses
Zero revenue leaves Galmed without an operating base to fund research, administration, or commercialization. Persistent losses, including renewed deterioration in 2025 and TTM, make the path to self-sustaining profitability dependent on successful pipeline execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Minimal Leverage
Near-zero debt limits interest obligations and reduces balance-sheet risk while Galmed funds development. This provides greater financial flexibility than a highly leveraged biotech, although the benefit is constrained by ongoing cash burn.
Read all positive factors
Galmed Pharmaceuticals (GLMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.97M
Dividend YieldN/A
Average Volume (3M)84.25K
Price to Earnings (P/E)―
Beta (1Y)2.15
Revenue GrowthN/A
EPS Growth71.38%
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-16.00
Shares Outstanding1,041,565
10 Day Avg. Volume86,643
30 Day Avg. Volume84,246
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.51
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-12.48
Revenue Forecast (FY)$5.72M
Galmed Pharmaceuticals Business Overview & Revenue Model
Company Description
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase II...
How the Company Makes Money
null...
Galmed Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -11.25M | -10.31M | -7.42M | -6.87M | -17.62M | -32.38M |
| Net Income | -11.12M | -10.31M | -7.52M | -6.91M | -17.87M | -32.47M |
Balance Sheet | ||||||
| Total Assets | 16.03M | 18.63M | 18.50M | 16.63M | 16.56M | 36.60M |
| Cash, Cash Equivalents and Short-Term Investments | 15.45M | 18.16M | 15.33M | 12.64M | 13.79M | 34.81M |
| Total Debt | 0.00 | 0.00 | 0.00 | 41.00K | 215.00K | 229.00K |
| Total Liabilities | 2.08M | 2.85M | 2.17M | 2.75M | 3.14M | 6.11M |
| Stockholders Equity | 13.95M | 15.78M | 16.33M | 13.88M | 13.42M | 30.50M |
Cash Flow | ||||||
| Free Cash Flow | -7.68M | -6.32M | -5.88M | -6.14M | -18.50M | -32.90M |
| Operating Cash Flow | -7.68M | -6.32M | -5.88M | -6.14M | -18.50M | -32.89M |
| Investing Cash Flow | -2.99M | -3.38M | -1.11M | 800.00K | 17.56M | 11.46M |
| Financing Cash Flow | 7.51M | 9.03M | 8.79M | 6.18M | 70.00K | 17.37M |
Galmed Pharmaceuticals Technical Analysis
Positive
0.51
Price Trends
4.51
Positive
4.77
Positive
5.68
Negative
Market Momentum
-0.01
Positive
55.94
Neutral
40.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GLMD, the sentiment is Positive. The current price of 0.51 is below the 20-day moving average (MA) of 4.51, below the 50-day MA of 4.51, and below the 200-day MA of 5.68, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 55.94 is Neutral, neither overbought nor oversold. The STOCH value of 40.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GLMD.
Galmed Pharmaceuticals Risk Analysis
Galmed Pharmaceuticals disclosed 77 risk factors in its most recent earnings report. Galmed Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Galmed Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $3.57M | -0.02 | -438.03% | ― | ― | 53.95% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $9.48M | -0.35 | -292.33% | ― | ― | 98.98% | |
44 Neutral | $4.97M | -0.29 | -64.10% | ― | ― | 71.38% | |
44 Neutral | $7.25M | -0.07 | 261.84% | ― | -21.49% | 84.62% | |
42 Neutral | $4.54M | >-0.01 | 764.53% | ― | 135.52% | 85.50% |
* Healthcare Sector Average
GLMD
Galmed Pharmaceuticals
4.56
-7.20
-61.22%
AIM
AIM ImmunoTech
0.25
-2.43
-90.58%
JAGX
Jaguar Animal Health
0.87
-62.83
-98.63%
QNRX
Quoin Pharmaceuticals
4.99
-2.29
-31.47%
SILO
Silo Pharma
2.74
-7.27
-72.63%
CLDI
Calidi Biotherapeutics
1.34
-25.86
-95.07%
Galmed Pharmaceuticals Corporate Events
Galmed’s Colospan Unit Reports Successful First-in-Human Study for New Colorectal Surgery Platform
Aug 19, 2026
On August 19, 2026, Colospan Ltd., Galmed Pharmaceuticals’ wholly owned subsidiary, reported completion of a first-in-human, single-arm feasibility study of a novel intraoperative colon tissue quality assessment technology in 32 colorectal c...
Galmed Reports Aramchol–Xtandi Combo Boosts Prostate Cancer Cell Death in Pre-Clinical Study
Aug 17, 2026
On August 17, 2026, Galmed Pharmaceuticals reported pre-clinical data showing that combining its SCD1 inhibitor Aramchol with leading prostate cancer drug enzalutamide (Xtandi) produced a three- to four-fold increase in cell death versus enzalutam...
Galmed Pharmaceuticals to Enact 1-for-8 Reverse Share Split Effective August 19, 2026
Aug 14, 2026
Galmed Pharmaceuticals said it will implement a 1‑for‑8 reverse share split of its ordinary shares, effective for trading on the Nasdaq Capital Market starting Wednesday, August 19, 2026. The move consolidates every eight existing ordi...
Galmed Pharmaceuticals Wins Nasdaq Extension to Regain $1 Bid Price Compliance
Jul 31, 2026
On July 30, 2026, Galmed Pharmaceuticals reported it had received a notice from Nasdaq granting an additional 180-day period, until January 25, 2027, to regain compliance with the exchange’s $1 minimum bid price requirement. The company had ...
Galmed Pharmaceuticals Drops Yissum License to Sharpen Focus on Colospan and Aramchol
Jul 29, 2026
Galmed Pharmaceuticals Ltd. is a biopharmaceutical company focused on gastrointestinal and liver disease treatments, advancing its Colospan device and Aramchol drug candidate in specialized digestive and hepatic markets. Through its Galmed Researc...
Galmed Unveils High-Exposure Orally Dispersible Aramchol Formulation for Parkinson’s Disease
Jul 28, 2026
On July 28, 2026, Galmed Pharmaceuticals, a clinical-stage biopharma and medical device company focused on gastrointestinal, cardiometabolic and oncology diseases, highlighted its lead SCD1 inhibitor Aramchol and its GI device CG-100 as part of a ...
Galmed Pharmaceuticals Sets August 26, 2026 Annual Meeting to Approve Governance and Structural Changes
Jul 22, 2026
On July 22, 2026, Galmed Pharmaceuticals announced it will hold its Annual General Meeting of shareholders in Ramat Gan, Israel, on August 26, 2026. Shareholders of record as of the close of trading on July 27, 2026, will be entitled to vote, with...
Galmed Pharmaceuticals Unveils Cardiac-Targeted Aramchol LNP Breakthrough
Jul 17, 2026
On July 16, 2026, Galmed Pharmaceuticals reported a breakthrough lipid nanoparticle formulation of its SCD1 inhibitor Aramchol that redirects the drug from liver hepatocytes to heart muscle. Developed with Barcode Nanotech using FDA-approved lipid...
Galmed Pharmaceuticals Reports Wider Q1 2026 Loss Amid Higher R&D Spending
Jul 8, 2026
Galmed Pharmaceuticals filed a Form 6-K in early July 2026, providing unaudited condensed consolidated financial statements for the quarter ended March 31, 2026. The filing gives investors a snapshot of the company’s financial position despi...
Galmed Pharmaceuticals Closes Amended All-Cash Colospan Acquisition With Earnout Structure
Jun 22, 2026
On June 22, 2026, Galmed Pharmaceuticals amended its previously announced deal to acquire Colospan Ltd., agreeing to replace a planned $2.0 million share issuance with an additional $800,000 in cash so that Colospan shareholders and certain SAFE i...
Galmed Pharmaceuticals to Acquire Colospan and Commit $6 Million to European Expansion
Jun 8, 2026
On June 8, 2026, Galmed Pharmaceuticals signed a share purchase agreement to acquire all outstanding shares of Israeli company Colospan Ltd., with closing expected in the second quarter of 2026, for $2.5 million in cash and $2 million in Galmed or...
Galmed and Tissue Dynamics Reveal New Metabolic Target for Cardiac Fibrosis With Aramchol Combo
Jun 2, 2026
On June 2, 2026, Galmed Pharmaceuticals and Tissue Dynamics reported preclinical data showing that a combination of Aramchol Meglumine, an SCD1 inhibitor, with a selective PPARα agonist reduced fibrotic burden about fourfold in inflammatory h...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.